文献速递肿瘤 PET/CT

18F-DCFPyL PET/CT在前列腺癌生化复发患者中的显像研究

18F-DCFPyL PET/CT Imaging in Patients with Biochemically Recurrent Prostate Cancer After Primary Local Therapy.
PubMed 文献 · J Nucl Med · 2019-11-01

这项前瞻性研究纳入90例根治性局部治疗后生化复发且常规影像阴性的前列腺癌患者,行18F-DCFPyL PSMA PET/CT,70例(77.8%)阳性,共287个病灶;PSA≥2.0 ng/mL时检出率94%,PSA 0.2–<0.5 ng/mL时47.6%。术后患者PSA、PSA倍增时间及PSA速率与PET结果相关。

要点

  • 18F-DCFPyL PET/CT在生化复发前列腺癌中检出率高,总体阳性率77.8%。
  • PSA<0.5 ng/mL患者约50%阳性,PSA≥2.0 ng/mL检出率达94%。
  • 术后患者PSA、PSA倍增时间和PSA速率与PET结果及病变范围相关。

核心结论

  • 18F-DCFPyL PET/CT对生化复发前列腺癌定位病灶具有高检出率,在PSA<0.5 ng/mL患者中约50%阳性,可能显著影响临床管理。
  • 术后患者中该显像与PSA、PSA倍增时间及PSA速率相关,提示可能具有预后价值。

研究设计与样本

  • 前瞻性、机构审查委员会批准的单中心研究,纳入90例根治性局部治疗后生化复发且常规影像阴性的前列腺癌患者。
  • 患者中位PSA为2.5 ng/mL(范围0.21–35.5 ng/mL),既往根治性前列腺切除术38例、放疗27例、两者联合25例,排除接受雄激素剥夺治疗者。
  • 患者静脉注射18F-DCFPyL(299.9±15.5 MBq)后2小时行全身PET/CT。

主要发现

  • 70例(77.8%)PSMA PET阳性,共识别287个病灶:前列腺床37个、淋巴结208个、骨或器官远处部位42个。
  • PSA>0.2至<0.5、0.5至<1.0、1至<2.0、≥2.0 ng/mL的检出率分别为47.6%(10/21)、50%(5/10)、88.9%(8/9)、94%(47/50)。
  • 术后患者中PSA、PSA倍增时间及PSA速率与PET结果相关,并与病变范围(盆腔内vs盆腔外)相关;放疗后患者中未观察到相同相关性。
  • 高分级与低分级原发肿瘤(Gleason评分≥4+3 vs <3+4)之间阳性扫描率无显著差异;40%(28/70)患者复发经组织学确认。

关键数值与推荐

  • 按患者分析,组织病理学验证的阳性预测值为93.3%(95%CI 77.6%–99.2%)。
  • 组织学联合影像/临床随访验证的阳性预测值为96.2%(95%CI 86.3%–99.7%)。

临床怎么用

  • 对根治性局部治疗后生化复发且常规影像阴性的前列腺癌患者,可考虑行18F-DCFPyL PET/CT定位复发灶。
  • PSA较低(<0.5 ng/mL)时仍有约50%阳性率,PSA≥2.0 ng/mL时检出率更高,可据此与患者沟通显像预期。
  • 术后患者可结合PSA、PSA倍增时间及PSA速率预判PET阳性可能性及病变范围。

局限性

  • 9例不确定病灶在本研究中按阴性计,可能低估检出率。
  • 仅40%(28/70)阳性患者复发经组织学确认,部分阳性预测值依赖影像/临床随访。
  • 放疗后患者中PSA相关参数与PET结果未见相同相关性,该亚组样本量有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Our objective was to investigate the lesion detection rate of 18F-DCFPyL PET/CT, a prostate-specific membrane antigen (PSMA)-targeted PET agent, in patients with biochemically relapsed prostate cancer after primary local therapy. Methods: This was a prospective institutional review board-approved study of 90 patients with documented biochemical recurrence (median prostate-specific antigen [PSA], 2.5 ng/mL; range, 0.21-35.5 ng/mL) and negative results on conventional imaging after primary local therapies, including radical prostatectomy (n = 38), radiation (n = 27), or a combination of the two (n = 25). Patients on androgen deprivation therapy were excluded. Patients underwent whole-body 18F-DCFPyL PET/CT (299.9 ± 15.5 MBq) at 2 h after injection. The PSMA PET lesion detection rate was correlated with PSA, PSA kinetics, and original primary tumor grade. Results: Seventy patients (77.8%) showed positive PSMA PET results, with a total of 287 lesions identified: 37 prostate bed foci, 208 lesions in lymph nodes, and 42 in distant sites in bones or organs, Eleven patients had negative results, and 9 patients showed indeterminate lesions, which were considered negative in this study. The detection rates were 47.6% (n = 10/21), 50% (n = 5/10), 88.9% (n = 8/9), and 94% (n = 47/50) for PSA levels of >0.2 to <0.5, 0.5 to <1.0, 1 to <2.0, and ≥2.0 ng/mL, respectively. In postsurgical patients, PSA, PSA doubling time, and PSA velocity correlated with PET results, but the same was not true for postradiation patients. These parameters also correlated with the extent of disease on PET (intrapelvic vs. extrapelvic). There was no significant difference in the rate of positive scans between patients with higher-grade and lower-grade primary tumors (Gleason score of ≥4 + 3 vs. <3 + 4). Tumor recurrence was histology-confirmed in 40% (28/70) of patients. On a per-patient basis, positive predictive value was 93.3% (95% confidence interval, 77.6%-99.2%) by histopathologic validation and 96.2% (95% confidence interval, 86.3%-99.7%) by the combination of histology and imaging/clinical follow-up. Conclusion:18F-DCFPyL PET/CT imaging offers high detection rates in biochemically recurrent prostate cancer patients and is positive in about 50% of patients with a PSA level of less than 0.5 ng/mL, which could substantially impact clinical management. In postsurgical patients, 18F-DCFPyL PET/CT correlates with PSA, PSA doubling time, and PSA velocity, suggesting it may have prognostic value. 18F-DCFPyL PET/CT is highly promising for localizing sites of recurrent prostate cancer.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Mena E, Lindenberg ML, Turkbey IB, et al. 18F-DCFPyL PET/CT Imaging in Patients with Biochemically Recurrent Prostate Cancer After Primary Local Therapy. J Nucl Med. 2019. PMID: 31676732. doi:10.2967/jnumed.119.234799

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。